慢性髓细胞白血病在尼洛替尼的早期动态预测深度分子反应。
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.
发表日期：2022 Oct 13
作者：
Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-Ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara
来源：
npj Systems Biology and Applications
摘要：
慢性髓系白血病（CML）是由BCR-ABL1酪氨酸激酶引起的一种髓系增生性疾病。尽管包括尼洛替尼在内的ABL1特异性酪氨酸激酶抑制剂（TKI）已经极大地改善了CML患者的预后，但TKI的有效性取决于患者个体情况。在本研究中，我们发现可以通过使用我们的简单动力学模型的估计参数和两项常见实验室指标来将不同尼洛替尼反应的患者进行分类。此外，我们提出的方法仅使用在尼洛替尼治疗期间的三个最初时间点收集的数据即可高度准确地识别未达到治疗目标的患者。由于我们的模型依赖于TKI反应的一般特性，因此我们的框架适用于接受前线尼洛替尼或其他TKI治疗的CML患者。©2022年作者。
Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CML, the TKI efficacy depends on the individual patient. In this work, we found that the patients with different nilotinib responses can be classified by using the estimated parameters of our simple dynamical model with two common laboratory findings. Furthermore, our proposed method identified patients who failed to achieve a treatment goal with high fidelity according to the data collected only at three initial time points during nilotinib therapy. Since our model relies on the general properties of TKI response, our framework would be applicable to CML patients who receive frontline nilotinib or other TKIs.© 2022. The Author(s).